EUCTR2026-000201-13-3RD Investigational Regimen Dysentery Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines EUCTR2026-000201-13-3RD—Long-Term Immunogenicity of the altSonflex1-2-3 Shigella vaccine in African children—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why EUCTR2026-000201-13-3RD is a hot trial to watch

Dysentery is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. EUCTR2026-000201-13-3RD is notable because it tests Investigational Regimen in a Phase 2 design while Anti-serotype specific Shigella lipopolysaccharide (LPS)/Oantigen (OAg)* serum immunoglobulin G (IgG), as measured by GVGH enzyme-linked immunosorbent assay (ELISA). *S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes will be tested. serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Non-Randomized, masking is not reported, and the intervention model is not reported. Enrollment of 179 participants across the reported study geography shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Anti-serotype specific Shigella lipopolysaccharide (LPS)/Oantigen (OAg)* serum immunoglobulin G (IgG), as measured by GVGH enzyme-linked immunosorbent assay (ELISA). *S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes will be tested. — At 12, 24, and 36 months after last vaccination.
• Secondary: Not Applicable — Not Applicable

Benchmark readouts in the surrounding field

• Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection (Phase 3): Functional cure(at week 72) = 19.0 %
• A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection (Phase 2): structured result record indexed; verify the endpoint-level record before cross-trial comparison.
• Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea (Phase 3): ALT normalization(at week 48) = 38.7 % ; ALT normalization(at week 48) = 55.0 %

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Investigational Regimen — structured asset context should be refreshed as the program evolves.

Company & Deal Intelligence context: GlaxoSmithKline Biologicals SA — http://www.gsk-bio.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

EUCTR2026-000201-13-3RD is a focused lens on Dysentery development. Its value will be determined by whether Investigational Regimen can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.